15.78  0.04 (0.25%)		04-26 16:00
Open: 15.78 High: 16 Volume: 53,721		Pre. Close: 15.74 Low: 15.06 Market Cap: 993(M)

Short term
Mid term
Targets	6-month :	19.37	1-year :	22.63
Resists	First :	16.59	Second :	19.37
Pivot price	15.27
Supports	First :	14.74	Second :	13.6
MAs	MA(5) :	15.79	MA(20) :	15.09
	MA(100) :	12.89	MA(250) :	0
MACD	MACD :	0.4	Signal :	0.3
%K %D	K(14,3) :	68.7	D(3) :	69.6
RSI	RSI(14): 63.4
52-week	High :	17.02	Low :	7.99

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ABVX ] has closed below upper band by 19.0%. Bollinger Bands are 16.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	16.02 - 16.08	16.08 - 16.14
Low:	14.89 - 14.97	14.97 - 15.03
Close:	15.65 - 15.77	15.77 - 15.88

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Thu, 26 Oct 2023
Citi Appointed as Depositary Bank for Abivax SA's ADR Program - Business Wire

Tue, 24 Oct 2023
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market - Yahoo Finance

Tue, 24 Oct 2023
Abivax Closes IPO on the Nasdaq Global Market - FinSMEs

Mon, 23 Oct 2023
Abivax Adds $236M to Show Its Anti-Inflammatory Med Can Stand Apart in Crowded Field - MedCity News

Fri, 20 Oct 2023
4 Firms Guide French Biotech Firm Abivax's $236M US IPO - Law360

Fri, 20 Oct 2023
Latham Watkins Advises on Abivax IPO on the Nasdaq Global Market - Latham & Watkins LLP -

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	63 (M)
Held by Insiders	2.912e+007 (%)
Held by Institutions	0 (%)
Shares Short	105 (K)
Shares Short P.Month	0 (K)

EPS	-1.2725e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-4 %
Return on Assets (ttm)	16.7 %
Return on Equity (ttm)	-39.6 %
Qtrly Rev. Growth	4.49e+006 %
Gross Profit (p.s.)	-0.07
Sales Per Share	-99.6
EBITDA (p.s.)	0
Qtrly Earnings Growth	-3.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-97 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.16
Price to Cash Flow	7.38

Dividend	0
Forward Dividend	143020
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.